Stages

Chordoma stages

After a chordoma diagnosis, the next step often is to find out the cancer's extent. This also is called the cancer's stage. Staging is the process health professionals use to describe how much cancer is in the body and where it is. Imaging tests can help measure the tumor. Biopsies may be done to look at the cancer cells. Your healthcare team uses the cancer stage to help create your treatment plan.

Chordoma staging might be done using different staging systems. Examples of systems include the:

  • Enneking system, which has three stages.
  • American Joint Committee on Cancer (AJCC) system, which has four stages.

Staging terms

For chordoma, staging usually looks at a few factors. The AJCC system refers to these as T, N and M.:

  • T. The size of the tumor.
  • N. Whether the tumor has spread to nearby tissues or lymph nodes.
  • M. Whether the cancer has spread to other parts of the body.

A lower stage number, no matter which staging system is used, means the cancer is less advanced. This means it's smaller, growing slowly and has not spread from the original tumor area. A higher stage number means the cancer is larger, growing more quickly or has spread.

Health professionals also look at how aggressive tumor cells look under a microscope. This is known as the tumor's grade (G).

A lower grade number, no matter which staging system is used, means a less aggressive, slower growing cancer. A higher grade number means a more aggressive, faster growing cancer.

  • The Enneking system has two grades.
  • The AJCC system has four grades.

Staging also might include the type of chordoma because it can relate to how aggressive it may be. Dedifferentiated and poorly differentiated chordomas tend to be more aggressive than conventional, also called classic and classical chordomas or chondroid chordomas. And chondroid chordomas tend to be more aggressive than conventional chordomas.

You may hear the term "end-stage chordoma." This refers to a chordoma that cannot be cured or managed with treatment. End-stage cancer treatment focuses on controlling pain and other symptoms to improve comfort.

Chordoma prognosis

A cancer prognosis tells you how likely it is that the cancer can be cured. Your healthcare team can get a general sense of your prognosis from staging. But the stage can't tell your future. Your personal prognosis may depend on:

  • Biopsy results.
  • How much of the tumor can be taken out during surgery.
  • The cancer's stage and grade.

Talk with your healthcare team about your prognosis if you want to know what to expect. Your healthcare team members can explain what they consider when thinking about your prognosis.

Oct. 17, 2025

Living with cordoma?

Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community.

Sarcoma Discussions

worriedgirl35
Possible liposarcoma?

14 Replies Fri, Oct 17, 2025

me67
Undifferentiated Pleomorphic Sarcoma: Anyone else want to share?

132 Replies Thu, Oct 16, 2025

Colleen Young, Connect Director
Diagnosed with sarcoma? Let's share

994 Replies Sat, Sep 27, 2025

See more discussions
  1. Elsevier Point of Care. Clinical Overview: Rare central nervous system tumors. https://www.clinicalkey.com. Accessed Nov. 20, 2024.
  2. Bone cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418. Accessed Aug. 21, 2025.
  3. Winn HR, ed. Youmans and Winn Neurological Surgery. 8th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 20, 2024.
  4. Zenonos GA. Chordoma of the skull base. https://www.uptodate.com/contents/search. Accessed Aug. 21, 2025.
  5. Chordoma. National Cancer Institute. https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-bone-tumors/chordoma. Accessed Aug. 21, 2025.
  6. Barber SM, et al. Chordoma — Current understanding and modern treatment paradigms. Journal of Clinical Medicine. 2021; doi:10.3390/jcm10051054.
  7. Banks C, et al. ICAR: Endoscopic skull-base surgery. International Forum of Allergy & Rhinology. 2019; doi:10.1002/alr.22326.
  8. Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/stereotactic. Accessed Jan. 29, 2025.
  9. Dickerson TE, et al. Recurrent metastatic chordoma to the liver: A case report and review of the literature. Current Oncology. 2022; doi:10.3390/curroncol29070367.
  10. Song PH, et al. Symptom burden and life challenges reported by adult chordoma patients and their caregivers. Quality of Life Research. 2017; doi:10.1007/s11136-017-1544-2.
  11. Young VA, et al. Clinical study: Characteristics and patterns of metastatic disease from chordoma. Sarcoma. 2015; doi:10.1155/2015/517657.
  12. Alshammari J, et al. Clival chordoma with an atypical presentation: A case report. Journal of Medical Case Reports. 2012; doi:10.1186/1752-1947-6-410.
  13. Dudhe S, et al. Challenging the giant: A case report on a huge sacrococcygeal chordoma and its radiological insights. Radiology Case Reports. 2025; doi:10.1016/j.radcr.2024.10.157.
  14. Zhou Y, et al. The clinical outcomes for chordomas in the cranial base and spine: A single center experience. Medicine. 2019; doi:10.1097/MD.0000000000015980.
  15. Medical oncologic treatment of spinal malignancies and outcomes. Video. Mayo Clinic; 2023.
  16. Murphey MD, et al. Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation. Skeletal Radiology. 2023; doi:10.1007/s00256-022-04158-7.
  17. Baig Mirza A, et al. Surgical management of spinal chordoma: A systematic review and single-center experience. World Neurosurgery. 2021; doi:10.1016/j.wneu.2021.09.001.
  18. Court C, et al. Management of chordoma of the sacrum and mobile spine. Orthopaedics & Traumatology: Surgery & Research. 2022; doi:10.1016/j.otsr.2021.103169.
  19. Goumenos S, et al. Clinical outcome after surgical treatment of sacral chordomas: A single-center retrospective cohort of 27 patients. Cancers. 2024; doi:10.3390/cancers16050973.
  20. Garofalo F, et al. The unresolved case of sacral chordoma: From misdiagnosis to challenging surgery and medical therapy resistance. Annals of Coloproctology. 2014; doi:10.3393/ac.2014.30.3.122.
  21. Zhang J, et al. Intradural cervical chordoma with diffuse spinal leptomeningeal spread: Case report and review of the literature. European Spine Journal. 2018; doi:10.1007/s00586-017-5443-6.
  22. Passeri T, et al. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers. Journal of Neurosurgery. 2023; doi:10.3171/2023.1.JNS222180.
  23. Ma T, et al. Current understanding of brachyury in chordoma. BBA — Reviews on Cancer. 2023; doi:10.1016/j.bbcan.2023.189010.
  24. Elsamadicy AA, et al. The association of gender in the management and prognosis of vertebral and sacral chordoma: A SEER analysis. Journal of Clinical Medicine. 2025; doi:10.3390/jcm14051737.
  25. What is cancer? American Cancer Society. https://www.cancer.org/cancer/understanding-cancer/what-is-cancer.html. Accessed Aug. 31, 2025.
  26. Soule E, et al. Current management and image review of skull base chordoma: What the radiologist needs to know. 2021; doi:10.25259/JCIS_139_2021.
  27. CT scan. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/ct-scan/about/pac-20393675. Accessed Sept. 4, 2025.
  28. American College of Surgeons. Bone cancer. In: AJCC Cancer Staging System. American College of Surgeons; 2025. https://online.statref.com. Accessed Sept. 8, 2025.
  29. Dastgheyb SS, et al. A prospective phase I/II clinical trial of high-dose proton therapy for chordomas and chondrosarcomas. Advances in Radiation Oncology. 2024; doi:10.1016/j.adro.2024.101456.
  30. Childhood chordoma treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/bone/hp/child-chordoma-treatment-pdq. Accessed Sept. 9, 2025.
  31. Immunotherapy. American Cancer Society. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed Sept. 18, 2025.
  32. Shyam Sunder S, et al. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy. 2023; doi:10.1038/s41392-023-01469-6.
  33. Cancer survival rate: What it means for your prognosis. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20044517. Accessed Sept. 18, 2025.
  34. Cancer survivors: Care for your body after treatment. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-survivor/art-20044015. Accessed Sept. 18, 2025.
  35. Stacchioti S, et al. Best practices for the management of local-regional recurrent chordoma: A position paper by the Chordoma Global Consensus Group. Annals of Oncology. 2017; doi:10.1093/annonc/mdx05.
  36. Bone cancer. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/bone-cancer/symptoms-causes/syc-20350217. Accessed Sept. 11, 2025.
  37. Steffner RJ, et al. Staging of bone and soft-tissue sarcomas. Journal of the American Academy of Orthopedic Surgeons. 2018; doi:10.5435/JAAOS-D-17-00055.
  38. Terminal cancer. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/terminal-cancer. Accessed Sept 12, 2025.
  39. Cancer pain: Relief is possible. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-pain/art-20045118. Accessed Sept. 18, 2025.
  40. Health Education & Content Services. Chordoma overview. Mayo Clinic; 2025.
  41. Sahgal A, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: Preliminary outcomes. Neuro-Oncology. 2015; doi:10.1093/neuonc/nou347.
  42. Chhabra AM, et al. Proton therapy for spinal tumors: A consensus statement from the Particle Therapy Cooperative Group. International Journal of Radiation Oncology, Biology, Physics. 2024; doi:10.1016/j.ijrobp.2024.04.007.
  43. Maroufi SF, et al. Stereotactic radiosurgery in the management of skull base chordomas: A comprehensive systematic review and meta-analysis. Neurosurgical Focus. 2024; doi:10.3171/2024.2.FOCUS249.
  44. Ghaith, AK, et al. Impact of proton versus photon radiotherapy on overall survival in the management of spinal chordoma and mortality risk prediction: A nationwide analysis. Journal of Neuro-Oncology. 2025; doi:10.1007/s11060-025-05104-y.
  45. Myneni, S, et al. Exploring perspectives on skull base chordoma management: A modified Delphi approach to consensus. Journal of Neuro-Oncology. 2025; doi:10.1007/s11060-025-05088-9.
  46. Han Y, et al. Clinical differences among histological categories of sarcoma: Insights from 97,062 patients. Cancers (Basel). 2025; doi:10.3390/cancers17101706.
  47. Rodrigues ACLF, et al. Proton beam and carbon ion radiotherapy in skull base chordoma: A systematic review, meta-analysis and meta-regression with trial sequential analysis. Neurosurgical Review. 2024; doi:10.1007/s10143-024-03117-1.